Oppenheimer Initiates Coverage On Design Therapeutics with Outperform Rating, Announces Price Target of $18
Benzinga Newsdesk 9 months ago
NewsPrice TargetInitiationAnalyst Ratings
Oppenheimer analyst Trevor Allred initiates coverage on Design Therapeutics (NASDAQ:DSGN) with a Outperform rating and announces Price Target of $18.
Oppenheimer analyst Trevor Allred initiates coverage on Design Therapeutics (NASDAQ:DSGN) with a Outperform rating and announces Price Target of $18.